Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection

European Journal of Gastroenterology and Hepatology

Volumn 14, Issue 12, 2002, Pages 1377-1382

  Pellicano, Rinaldo ^a   Palmas, Franco ^a   Cariti, Giuseppe ^b   Tappero, Gianfranco ^c   Boero, Marco ^d   Tabone, Marco ^e   Suriani, Renzo ^f   Pontisso, Patrizia ^g   Pitaro, Michele ^h   Rizzetto, Mario ^a  

^a UOADU Gastro Hepatology   (Italy)

^b AMEDEO DI SAVOIA HOSPITAL   (Italy)

^c GRADENIGO HOSPITAL   (Italy)

^d S GIOVANNI BOSCO HOSPITAL   (Italy)

^e MAURIZIANO HOSPITAL   (Italy)

^f UOA Gastroenterology   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h Industria Farmaceutica Serono   (Italy)

Author keywords

Chronic hepatitis; HCV; Hepatitis C virus; Interferon

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA1A INTERFERON; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME BLOOD LEVEL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HUMAN; INSOMNIA; MALE; PARESTHESIA; PRIORITY JOURNAL; RETREATMENT; TREATMENT OUTCOME; VERTIGO;

ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; RECURRENCE; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0036923777     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200212000-00015     Document Type: Article

References (20)

1. National Institutes of Health Consensus Development Conference Panel Statement. Management of hepatitis C. Hepatology 1997; 26(Suppl 1):2S-10S.
2. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-965.
4. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672.
5. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology 1994; 107:812-817.
6. Petska S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Ann Rev Biochem 1987; b:727-777.
7. Bocci V. Physiochemical and biologic properties of interferons and their potential use in drug delivery systems. Crit Rev Drug Carrier Syst 1992; 9:91-133.
8. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, et al. Neutralizing antibodies to recombinant alpha interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13:146-150.
9. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
10. EASL International Consensus Conference on hepatitis C. J Hepatol 1999; 30:956-961.
11. Cirelli R, Herne K, Tyring SK. Interferons: An overview of their pharmacology. Clin Immunother 1996: 5(Suppl 1):22-30.
12. Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16:489-499.
13. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996; 16:759-764.
14. Scagnolari C, Bellomi F, Turriziani O, Bagnato F, Tomassini V, La Volpe V, et al. Neutralizing and binding antibodies to IFN-beta: Relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations. J Interferon Cytokine Res 2002; 22:207-213.
15. Habersetzer F, Marcellin P, Boyer N, Zoulim F, Chossegros P, Erlinger S, et al. Recombinant interferon beta for the treatment of chronic hepatitis C. Hepatology 1995; 225:49.
16. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L, et al. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999; 46:3216-3222.
17. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo G. Therapy of hepatitis C: Re-treatment with alpha interferon. Hepatology 1997; 26(Suppl 1):137S-142S.
18. Canthers RL, Emerson SS. Therapy of hepatitis C: Meta-analysis of interferon alpha 2-b trials. Hepatology 1997; 26(Suppl 1):83S-88S.
19. Habersetzer F, Boyer N, Marcellin P, Bailly F, Ahmed SN, Alam J, et al. A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver 2000; 20:437-441.
20. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. A dose ranging study of pegylated interferon alpha-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32:647-653.